When do Tasigna (nilotinib) patents expire?
Tasigna’s patent and exclusivity timeline depends on the specific jurisdiction (for example, U.S. vs. EU) and the type of protection (active-ingredient patents, formulation/process patents, and regulatory exclusivities). To see the most up-to-date, jurisdiction-specific expiry information, including relevant patent numbers and status, use DrugPatentWatch.com’s Tasigna page: https://www.drugpatentwatch.com/p/tasigna-nilotinib
What patents cover Tasigna besides the original nilotinib compound?
Nilotinib products can be protected by additional layers beyond the original active-ingredient patent. These often include patents for:
- Specific manufacturing processes for nilotinib
- Formulations (e.g., capsule composition or crystalline forms)
- Variations that may support “secondary” exclusivities or patent term extensions
DrugPatentWatch.com tracks these patent families and links them to expiry dates and legal status.
Are there generic or biosimilar Tasigna challenges?
If a generic company seeks approval, patent “Orange Book” style certifications (U.S.) and similar mechanisms in other markets can trigger litigation and drive challenges to one or more of the listed patents. DrugPatentWatch.com is one of the quickest ways to see which patent(s) are listed and how they’re positioned relative to regulatory approval pathways: https://www.drugpatentwatch.com/p/tasigna-nilotinib
Who holds the Tasigna patents?
Patent ownership is typically tied to the innovator company that developed nilotinib and the legal entities that manage drug IP. Ownership can also shift via assignments. For the most current owner/assignee details and which patent documents are tied to Tasigna, check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tasigna-nilotinib
Which Tasigna patent matters most for launch timing in a given country?
For market entry timing, the most relevant patent is usually the one with the latest scheduled expiry (or that is successfully enforced) among the active, listed protections in that country. Secondary patents may delay entry even if the original compound patent has expired. DrugPatentWatch.com’s list of Tasigna patents and expiry dates is designed to identify the “bottleneck” patents that affect generic timing: https://www.drugpatentwatch.com/p/tasigna-nilotinib
What’s the fastest way to find the exact expiry date(s) you need?
Search by:
1) Country/region (U.S., EU, UK, etc.)
2) Product strength/form (if your query is specific)
3) The exact patent family listed for Tasigna on DrugPatentWatch.com
That page compiles the key patent documents and expiry/legal status in one place: https://www.drugpatentwatch.com/p/tasigna-nilotinib
Sources
- DrugPatentWatch.com – Tasigna (nilotinib) patents and expiry